SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverBDX
HealthcareNYSEUSD

Becton Dickinson

$001234567890012345678900123456789.0012345678900123456789+10.2%
52w low (est.) $132.17$197.28 52w high (est.)
Peers
Market data
Market cap
$41.87B
52-week range
$127.59 – $187.35
Beta (vs market)
0.27
Sector
Healthcare
Valuation
P/E ratio
26.5x
DCF fair value
$93.40
Margin of safety
-41.6%
Forward P/E
11.3x
PEG ratio
1.11
Dividend yield
2.76%
Quality & efficiency
Moat score
49/100
Return on equity
6.7%
Profit margin
5.1%
Debt / equity
0.72
Growth & analysts
Revenue growth (YoY)
+5.2%
Analyst target
$176.92
Target upside
+10.6%
Analysts covering
12

About Becton Dickinson

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Valuation

ValueGrowthProfitHealthIncome35QUALITY
Overall Rating
35
Reduce
Reduce
Moat Score49
DCF Intrinsic Value
$93.40-41.6% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$41.87B
P/E Ratio
26.5
Dividend Yield
2.76%
Revenue Growth
+5.2%
Profit Margin
5.1%
ROE
6.7%
Debt / Equity
0.72
Beta
0.27
Dividend Aristocrats
vs Healthcare sector:P/E 27 vs 28 · cheaperMoat 49 vs 7Yield 2.76% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · BDX